Researchers discovered a novel medication that lowers sugar levels and aids in burning fat without affecting appetite or muscle mass. This is significant for managing type 2 diabetes and obesity.
The study was conducted by experts from the Karolinska Institute in Sweden and is published in the journal Cell. The new compound functions differently than familiar medicines like “Ozempic.” Those drugs target the brain, reducing hunger, but may cause adverse effects: appetite loss, muscle mass decrease, and stomach issues.
The primary active component of the new drug is a laboratory analog of a $\beta_2$-agonist. This is a group of agents that stimulate $\beta_2$-adrenoceptors in muscle tissue; typically, they are used for respiratory tract ailments. Here, the scientists utilize their metabolic effect to boost glucose uptake by muscles without impacting hunger. Consequently, muscles process glucose more effectively. This mechanism lowers sugar levels and improves body composition.
Since this remedy acts differently than GLP-1 based preparations, it can be administered alone or alongside them. Phase I clinical trials confirmed its safety. The subsequent stage involves large-scale clinical testing.
About the Author
